ERAS short interest
Erasca Inc. · Healthcare · Biotechnology · settlement date 2026-09-30
| Shares short | 35,338,107 |
|---|---|
| Change vs prior report | 2,301,968 (+7.0%) |
| Change over six months | +18.2% |
| Days to cover | 6.87 (sector: 3.78) |
| Average daily volume | 5,143,537 |
| Rank in Healthcare | #260 of 922 by days to cover |
ERAS short interest, last 12 months
| Settlement | Shares short | Change | Days to cover | Avg daily volume |
|---|---|---|---|---|
| 2026-09-30 | 35,338,107 | +7.0% | 6.87 | 5,143,537 |
| 2026-09-15 | 33,036,139 | +5.8% | 7.65 | 4,316,648 |
| 2026-08-31 | 31,238,099 | +1.3% | 9.44 | 3,308,858 |
| 2026-08-14 | 30,847,289 | +3.0% | 10.01 | 3,080,346 |
| 2026-07-31 | 29,953,849 | -2.6% | 7.27 | 4,119,030 |
| 2026-07-15 | 30,766,629 | -4.8% | 5.88 | 5,230,546 |
| 2026-06-30 | 32,321,195 | +2.6% | 4.49 | 7,192,412 |
| 2026-06-15 | 31,493,422 | -1.2% | 5.77 | 5,461,564 |
| 2026-05-29 | 31,891,428 | +1.5% | 7.49 | 4,255,264 |
| 2026-05-15 | 31,425,335 | -2.0% | 6.73 | 4,670,591 |
| 2026-04-30 | 32,056,721 | -5.7% | 2.39 | 13,406,503 |
| 2026-04-15 | 33,974,829 | +13.7% | 6.07 | 5,601,062 |
| 2026-03-31 | 29,886,446 | +13.5% | 4.85 | 6,167,248 |
| 2026-03-13 | 26,340,417 | -3.5% | 5.48 | 4,807,956 |
| 2026-02-27 | 27,299,791 | -3.6% | 8.83 | 3,092,809 |
| 2026-02-13 | 28,314,016 | +10.4% | 6.34 | 4,463,627 |
| 2026-01-30 | 25,640,846 | -3.7% | 3.58 | 7,169,080 |
| 2026-01-15 | 26,637,035 | +30.0% | 2.20 | 12,081,005 |
| 2025-12-31 | 20,487,523 | +20.8% | 7.72 | 2,652,389 |
| 2025-12-15 | 16,962,442 | +3.6% | 7.08 | 2,394,640 |
| 2025-11-28 | 16,365,359 | +0.7% | 8.87 | 1,844,303 |
| 2025-11-14 | 16,250,251 | -0.7% | 10.97 | 1,480,911 |
| 2025-10-31 | 16,357,077 | +1.3% | 15.18 | 1,077,478 |
| 2025-10-15 | 16,144,526 | -6.0% | 5.61 | 2,880,149 |
| 2025-09-30 | 17,179,445 | -7.7% | 9.73 | 1,766,023 |
import finzdata as yf
yf.Ticker("ERAS").short_interest # every report since 2017
yf.Client().short_interest(["ERAS"], start="2018-01-01")Healthcare short interest · ERAS price history · Who owns ERAS · All short interest